Microbiome Therapeutics Innovation Group

07/13/2026

MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and expand availability of life-changing and life-saving FDA approved microbiome therapies to patients. To inquire about MTIG membership, visit:

Membership MTIG Membership All pharmaceutical and biotechnology companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products are eligible for consideration of membership in MTIG. All MTIG members must: Be seeking regulatory approval for at least one microbiome th...

07/07/2026

Built on decades of innovation and dedication, Nestlé Health Science was founded by people passionate about the power of nutrition. Through extensive research and development, working with healthcare providers and focusing on innovation, Nestle is bringing the latest advances in nutrition to the world. Learn about their work here:

Nestlé Health Science is a leader in the field of nutritional science, committed to redefining the management of health. Read more about our range of products.

07/01/2026

FDA-approved Microbiome Therapeutics (MT) have vast potential to help treat a wide range of diseases and conditions across gastrointestinal, neurological, immunological, oncological, and other indications. Learn about the differences between microbiome therapeutics and probiotic supplements here:

06/26/2026

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that helps people live healthier, happier lives. Learn more:

Microba delivers the only clinical-grade gut microbiome test, revealing health impacts and actions, backed by evidence from 1,500+ studies.

06/22/2026

Freya’s proprietary multi-omics data science platform, Dyscover™, provides deep insights into disease pathway-associated biomarkers and derivation of clinical candidates. See how the Dyscover™ platform is closing the data gap, de-risking clinical development and enabling innovation here:

By targeting immune mechanisms, we aim to restore healthy biological function and improve clinical outcomes for patients.

05/22/2026

Vedanta Biosciences' VE707 is a preclinical candidate for the prevention of Gram-negative infections, including those caused by AMR strains, that affect a wide range of vulnerable populations in areas such as oncology, urology, transplantation, and critical care. More info:

Vedanta is advancing first-in-class Live Biotherapeutic Products (LBP) to treat serious gastrointestinal diseases using defined consortia of bacteria.

05/18/2026

With clinical studies underway for allergic diseases, Siolta Therapeutics is broadening its portfolio in the “maternal-infant axis” by advancing programs for recurrent bacterial vaginosis and necrotizing enterocolitis. Learn more here:

Siolta Therapeutics is a clinical-stage company developing live biotherapeutics that target the core drivers of disease. Learn more.

05/13/2026

Did you know that approximately 1 in 13 children and 1 in 10 adults are affected by food allergies? Microbiome therapies currently in development have the potential to alter the gut microbiome to help treat or even reverse food allergies.

05/12/2026

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference https://bit.ly/4d6m0oJ

05/11/2026

As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients.

Améliorer la survie des patients grâce à une immunomodulation innovante Nous sommes une société au stade clinique, spécialisée dans les thérapies issuesdu microbiote dédiées aux patients atteints de cancer. Nos atouts Approche écosystème complet Focus sur l’oncologie Développement de ...